Treatment for high blood pressure: evidence and practice.

[1]  C. Furberg,et al.  JNC VI: timing is everything , 1997, The Lancet.

[2]  R. Collins,et al.  Reliable and unbiased assessment of the effects of calcium antagonists: importance of minimizing both systematic and random errors , 1997, Journal of hypertension.

[3]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[4]  R. Collins,et al.  Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding , 1997, Journal of Human Hypertension.

[5]  M. Rocco,et al.  Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. , 1996, JAMA.

[6]  L. Ferrucci,et al.  Calcium-channel blockade and incidence of cancer in aged populations , 1996, The Lancet.

[7]  J. Guralnik,et al.  Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old , 1996, The Lancet.

[8]  Furberg Cd,et al.  Corrections to the nifedipine meta-analysis. , 1996 .

[9]  T. Raghunathan,et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.

[10]  D. Reda,et al.  Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. , 1995, American journal of hypertension.

[11]  Lippincott Williams Wilkins,et al.  1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. , 1993, Hypertension.

[12]  C. Lewis,et al.  Treatment of Mild Hypertension Study: Final Results , 1993 .

[13]  P Barham,et al.  Management of raised blood pressure in New Zealand: a discussion document. , 1993, BMJ.

[14]  C. Bulpitt,et al.  Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. , 1993, BMJ.

[15]  C. Furberg,et al.  Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. , 1991, The American journal of cardiology.

[16]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[17]  S. MacMahon,et al.  The world health organization—International society of hypertension blood pressure lowering treatment trialists’ collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments , 1999, Current hypertension reports.

[18]  H. Matsuoka.  A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension--The GLANT Study. Study Group on Long-term Antihypertensive Therapy. , 1995, Hypertension research : official journal of the Japanese Society of Hypertension.

[19]  R. Collins,et al.  Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. , 1994, British medical bulletin.